TCGA-55-8513-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- IL6_JAK_STAT3_SIGNALING+0.390
- INTERFERON_GAMMA_RESPONSE+0.380
- COAGULATION+0.330
- COMPLEMENT+0.310
- KRAS_SIGNALING_DN+0.290
- INFLAMMATORY_RESPONSE+0.270
- BILE_ACID_METABOLISM+0.260
- MYOGENESIS+0.260
- KRAS_SIGNALING_UP+0.180
Top 10 suppressed
- E2F_TARGETS-0.740
- MYC_TARGETS_V1-0.740
- MYC_TARGETS_V2-0.680
- G2M_CHECKPOINT-0.660
- OXIDATIVE_PHOSPHORYLATION-0.570
- MTORC1_SIGNALING-0.530
- DNA_REPAIR-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.490
- GLYCOLYSIS-0.400
- PROTEIN_SECRETION-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-A4P8-01A-11R-A24X-07 | — | cohortA1 | 0.945 |
| 2 | TCGA-93-A4JP-01A-11R-A24X-07 | — | cohortA1 | 0.934 |
| 3 | TCGA-86-A4P7-01A-11R-A24X-07 | — | cohortA1 | 0.925 |
| 4 | TCGA-50-8457-01A-11R-2326-07 | — | cohortA1 | 0.915 |
| 5 | TCGA-55-8621-01A-11R-2403-07 | — | cohortA1 | 0.908 |
| 6 | ERR2208890 | — | — | 0.904 |
| 7 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.903 |
| 8 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.902 |
| 9 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.902 |
| 10 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |